Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Aphria in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Aphria. This N/A consensus rating has held steady for over two years.
Aphria, Inc. engages in the production and supply of medical cannabis. It operates through the following segments: Cannabis Operations, Distribution Operations, and Business Under Development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution Under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.